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during treatment of acute lymphoblastic leukemia (ALL) in
childhood. METHODS: Patients were age ﬁve years or older at
time of study and enrolled in Dana Farber Cancer Institute 95-
001 clinical trial. Parents-of-patients and clinicians, blinded to
each other, completed self-administered HUI questionnaires at
four assessment points during treatment: Induction of remission,
CNS prophylaxis, intensiﬁcation, and maintenance. Agreement
between parents and clinicians, for HUI3 single-attribute and
overall health-related quality of life (HRQL) utility scores, was
assessed using a single-measure two-way mixed model intra-class
correlation coefﬁcient (ICC) and paired t-test. Mean differences
in single-attribute and HRQL scores >0.05 and >0.03, respec-
tively, are clinically important. Statistical signiﬁcance was set at
p < 0.05. ICC results were interpreted as follows: >0.50 strong
agreement; 0.35–0.50 moderate agreement; 0.20–0.34 weak
agreement; 0.00–0.19 negligible agreement. RESULTS: There
were 375 patients who were surveyed (55.2% males). The
number of pairs of parent and clinician assessments varied by
assessment point (minimum = 104, maximum = 180). There was
moderate or better agreement between raters (p < 0.05) at all
assessment points for ambulation (ICC = 0.51–0.84) and pain
(ICC = 0.39–0.84). Weak or better agreement (p < 0.05) was
observed at all assessment points for vision (ICC = 0.23–0.79),
and emotion (ICC = 0.22–0.69). Inter-rater agreement for HRQL
ranged from weak to moderate (ICC = 0.31–0.50, p < 0.05).
There was no signiﬁcant agreement (p > 0.05) for dexterity at
any assessment point (ICC = 0.05–0.16) and for cognition at
Induction (ICC < 0.01). The mean difference (clinician minus
parent) was clinically important for HRQL (difference = 0.07, p
= 0.01) at Maintenance. CONCLUSIONS: Inter-rater agreement
varies, from none to strong, by both type of utility score and
assessment point. A clinically important mean difference in
HRQL scores was observed. Parent and clinician reports should
not be considered interchangeable. The results are consistent
with studies of ALL patients assessed after completion of
therapy.
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OBJECTIVES: The ﬁve-year mortality rate for a population of
adult brain tumor patients is typically high (≥50%). Tumor grade
is a well-known predictor for mortality: low-grade (LG) tumors
are associated with lower mortality rates than are high-grade
(HG) tumors. METHODS: Prospective study of consecutive
patients newly diagnosed with primary brain tumors attending
a single regional centre. A cross-sectional survey collected base-
line health status assessments for each patient after diagnosis,
and in most cases surgery, but before radiotherapy or chemother-
apy. Each participating patient completed a Health Utilities
Index (HUI) Mark 2 (HUI2) and Mark 3 (HUI3) 15-item self-
complete questionnaire, prior to encounter with assessing physi-
cian. The assessing physician, blind to patient’s assessment,
recorded a Karnofsky Performance Score (KPS) and a Mini-
Mental Status Examination (MMSE) score. The life status for
each patient was determined for the ﬁve-year period after assess-
ment. Proportional hazards models estimated the IHOD for dif-
ferences of: 0.10 in HUI utility scores; ten units in KPS; and ﬁve
units in MMSE. Statistical signiﬁcance was set at the 5% level.
RESULTS: HUI2 self-care was the only health status measure
associated with a signiﬁcant IHOD for LG tumors (n = 25): a
decrease of 0.10 in HUI2 self-care score being associated with a
30% IHOD (p = 0.023). Among patients with HG tumors (n =
56), 3 measures were independently signiﬁcant: KPS (20%
IHOD, p = 0.022); MMSE (26% IHOD, p = 0.015) and HUI3
dexterity (18% IHOD, p = 0.035). Two measures, together, were
signiﬁcant among HG patients: MMSE (29% IHOD, p = 0.007)
and HUI3 dexterity (20% IHOD, p = 0.020). CONCLUSION:
Only HUI measures were signiﬁcant predictors of IHOD for both
LG and HG patients. MMSE and HUI3 dexterity, in combina-
tion, were signiﬁcant predictors for HG patients. The latter is
evidence that patient- and physician-reported measures provide
important complementary types of information.
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OBJECTIVES: To assess economic appraisals of chemotherapy
regimens for metastatic colorectal cancer (mCRC) published in
peer-reviewed journals. METHODS: A PubMed search of
English-language documents published up to October 2004 was
conducted using the search terms: “chemotherapy”, “metasta-
tic”, “colorectal cancer”, and “economic”, “cost-effectiveness”,
or “cost-beneﬁt”. Additional publications were identiﬁed from
references, reviews, and meta-analyses. Publications were
reviewed for information on the type of cost analyses, year of
publication, journal, country, perspective, type of chemotherapy
assessed, data collection methods, sponsorship, and types of sen-
sitivity analyses conducted. RESULTS: Economic analyses were
published on eight regimens. Seven of the 14 published studies
were published from a UK perspective, and 2 each from a French
and a Dutch perspective; no study has been published from the
US perspective. Ten studies were cost-consequences and four
were cost-effectiveness analyses. Limited documentation was
provided on sources of costs for medical resource use. Adjust-
ments for quality of life were considered in sensitivity analyses
in two studies designed to inform guidance by the UK’s National
Institute of Clinical Excellence. Overall, drug costs accounted for
1%–37% of total expenditures for 5-ﬂourauracil + leucovorin
(5FU/LV) regimens, in contrast to 47%–83% of total expendi-
tures for newer combination regimens (e.g., irinotecan + 5FU/LV,
oxaliplatin +5FU/LV, capecitabine). No formal analyses were
published on Avastin (bevacizumab) or Erbitux (cetuximab).
Discounting for future costs and beneﬁts was not done in any
analysis. CONCLUSIONS: Some prominent novel regimens for
mCRC have no publicly available economic appraisal. Among
the few published studies on older regimens, most omit compo-
nents such as quality-of-life adjustments, discounting, and 
transparent statements on data sources for prices that are rec-
ommended in ISPOR’s statement on “Good Research Practices—
Modeling Studies.”
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OBJECTIVE: This study seeks to synthesize and identify gaps in
the economic literature of prostate cancer (PCA). METHODS:
English-language abstracts and articles published between 1990
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and mid-2005 were retrieved from MEDLINE, conference pro-
ceedings, and governmental databases using search terms
“prostate cancer”, “prostatic neoplasm”, or similar, combined
with a comprehensive list of cost-related search terms. Articles
that provided economic data at an individual or societal level
were retrieved in full text and analyzed by study type, design,
endpoints, results, and other characteristics. RESULTS: Of 1169
abstracts retrieved, 186 met the inclusion criteria, of which most
(133 articles, 71.5%) were published since 1999. More than half
of the economic evaluations were retrospective, based on chart
reviews and database analyses (101, 54.3%). Others were
prospective evaluations based on clinical trials or observational
studies (73, 39.2%), and economic modeling of PCA screening
strategies (12, 6.5%). Cost-of-illness studies were completed in
eight developed countries. Assessments of cost per treatment
and/or per cancer stage (16, 8.6%) and cost per patient (11,
5.9%) were conducted primarily in the U.S., as were cost studies
of mass screening (25, 13.4%) and diagnostic modalities (15,
8.1%). Cost evaluations of curative treatments (43, 23.1%)
focused primarily on androgen suppression therapy (13, 7.0%),
as well as radical prostatectomy (10, 5.4%), radiation therapy
(10, 5.4%), or combination therapies (10, 5.4%). Cost assess-
ments of palliative care (21, 11.3%) focused on hormonal
therapy (16, 8.6%). Studies of indirect costs, costs of pharma-
ceutical preventions (e.g. ﬁnasteride) and the economic impact
of recurrence after treatment failure were scarce or unavailable.
CONCLUSIONS: As the population ages and as earlier detec-
tion become more common, PCA is becoming a more important
focus of economic assessment. Cost comparisons among treat-
ments or diagnostic modalities will remain challenging without
standardized assessments of clinical outcomes that make evalu-
ation of treatment effectiveness comparable across regimens.
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A METHOD TO REMOVE CONTINUOUS ENROLLMENT
REQUIREMENT FROM PHARMAECONOMIC STUDIES
Baser O
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OBJECTIVE: Continuous enrolment requirement becoming a
“rule” rather than “exception” in pharmaeconomical studies.
However, continuous enrolment requirement contains potential
bias especially patients with incomplete data structurally differ-
ent from the ones with complete data. Moreover, for studies
involving rare diseases the requirement signiﬁcantly reduces
sample size and creates power issues. In this paper, we outline
the methodology which can be used to remove continuous
requirement. METHODS: This is a two stage method. First, we
estimate probability of being continuously enrolled using every
observation in our data set. This estimation can be done either
with parametric methods (such as logit, probit) or non-
parametric methods (such as Kaplan-Meier). Then according to
these probabilities we create a weight which is inverse of the esti-
mated probabilities at ﬁrst stage. Using these weights and only
observations which are continuously enrolled we estimate
weighted least square models at the second stage. Therefore
second stage regressions use probabilities containing information
from everybody at the ﬁrst stage. We showed that this eliminate
possible selection bias due to continuous enrolment. RESULTS:
We used medicare claim ﬁles for application. A total of 773
patients with incident cases of lung, prostate, colon and breast
cancer were analyzed for two years of cost. Continuous enrol-
ment requirement would decrease the sample size to 541 and
would create potential selection bias. We estimated the results
with and without continuous enrolment requirement and
showed that the results are statistically different from each other
(p = 0.000). CONCLUSIONS: Continuous enrolment require-
ment should not be applied blindly. Data sets created based on
this requirement yields consistent results if there is no systematic
differences between complete and incomplete observations.
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MODELING AND ESTIMATING PREFERENCES OVER
TREATMENTS FOR BREAST CANCER:APPLIED 
CONJOINT ANALYSIS WITH PHYSICIANS IN EUROPE AND
UNITED STATES
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OBJECTIVES: The relative importance of product attributes for
the treatment of breast cancer were derived by applying conjoint
analyses in the US and Europe. The possible differences of the
prescribing behavior between physicians in Europe and the US
were analyzed. METHODS: Hypothetical attributes for phar-
maceutical products to treat breast cancer in various disease
phases were developed. Besides efﬁcacy and side effects the costs
for the products were also included as an attribute. Orthogonal
scenarios were derived and implemented in the questionnaire.
Questions about physician’s background, prescribing behaviors
and socioeconomic parameters were also developed and pre-
tested. The ﬁnal survey was done in the US and ﬁve different
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